Taiho Oncology, Inc., announces FDA approval of INQOVI®.
On August 10th, 2020
ASTEX PHARMACEUTICALS, TAIHO ONCOLOGY, AND OTSUKA PHARMACEUTICAL ANNOUNCE FDA AND HEALTH CANADA APPROVAL OF INQOVI® (DECITABINE AND CEDAZURIDINE) TABLETS, ORAL HYPOMETHYLATING AGENT (HMA) THERAPY FOR INTERMEDIATE AND HIGH-RISK MDS AND CMML.
Additional information is available at: https://www.taihooncology.com/us/news/2020-07-inqovi-approval/
ASTEX PHARMACEUTICALS, TAIHO ONCOLOGY, AND OTSUKA PHARMACEUTICAL ANNOUNCE FDA AND HEALTH CANADA APPROVAL OF INQOVI® (DECITABINE AND CEDAZURIDINE) TABLETS, ORAL HYPOMETHYLATING AGENT (HMA) THERAPY FOR INTERMEDIATE AND HIGH-RISK MDS AND CMML.
Additional information is available at: https://www.taihooncology.com/us/news/2020-07-inqovi-approval/
No comments have been posted yet.